Sex-based differences in HIV type 1 pathogenesis

Journal of Infectious Diseases

Volumn 209, Issue SUPPL. 3, 2014, Pages

  Addo, Marylyn M ^a,c,d   Altfeld, Marcus ^b,e  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^c German Center for Infectious Diseases Research DZIF Standort Hamburg Luebeck Borstel   (Germany)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

HIV 1; Immune activation; interferon alpha; ISG; sex

Indexed keywords

ALPHA INTERFERON; ATAZANAVIR; EFAVIRENZ; RITONAVIR; TOLL LIKE RECEPTOR 7; TRANSCRIPTION FACTOR FOXP3;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4+ T LYMPHOCYTE; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENETIC DIFFERENCE; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; LYMPHOCYTE COUNT; MALE; PATHOGENESIS; PLASMACYTOID DENDRITIC CELL; POLITICS; PRIORITY JOURNAL; SEROCONVERSION; SEX DIFFERENCE; SOCIAL ASPECT; UPREGULATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

HIV-1; IMMUNE ACTIVATION; INTERFERON-ALPHA; ISG; SEX;

ANTI-HIV AGENTS; DISEASE SUSCEPTIBILITY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; SEX FACTORS;

EID: 84903547822     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu175     Document Type: Article

References (54)

1. Klein SL. Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. Bioessays 2012; 34: 1050-9.
2. UNAIDS Global summary of the HIV/AIDS epidemic UD, 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/ epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf. Accessed 14 April 2014.
3. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344:720-5.
4. Sterling TR, Lyles CM, Vlahov D, Astemborski J, Margolick JB, Quinn TC. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999; 180:666-72.
5. Delmas MC, Jadand C, De Vincenzi I, et al. Gender difference in CD4+ cell counts persist after HIV-1 infection. SEROCO Study Group. AIDS 1997; 11:1071-3.
6. Touloumi G, Pantazis N, Babiker AG, et al. Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS 2004; 18:1697-705.
7. Meditz AL, MaWhinney S, Allshouse A, et al. Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis 2011; 203:442-51.
8. Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, Greenblatt RM. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis 2002; 35:313-22.
9. Prins M, Robertson JR, Brettle RP, et al. Do gender differences in CD4 cell counts matter? AIDS 1999; 13:2361-4.
10. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV- 1 viral load and progression to AIDS. Lancet 1998; 352:1510-4.
11. Sodora DL, Gettie A, Miller CJ, Marx PA. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Hum Retroviruses 1998; 14(Suppl 1):S119-23.
12. Marx PA, Spira AI, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2:1084-9.
13. Smith SM, Mefford M, Sodora D, et al. Topical estrogen protects against SIV vaginal transmission without evidence of systemic effect. AIDS 2004; 18:1637-43.
14. Mugo NR, Heffron R, Donnell D, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS 2011; 25:1887-95.
15. Marston M, Newell ML, Crampin A, et al. Is the risk of HIV acquisition increased during and immediately after pregnancy? A secondary analysis of pooled HIV community-based studies from the ALPHA network. PLoS One 2013; 8:e82219.
16. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis 2013; 13:797-808.
17. Cu-Uvin S,Wright DJ, Anderson D, et al. Hormonal levels among HIV- 1-seropositive women compared with high-risk HIV-seronegative women during the menstrual cycle. Women's Health Study (WHS) 001 and WHS 001a Study Team. J Womens Health Gend Based Med 2000; 9:857-63.
18. Reichelderfer PS, Coombs RW, Wright DJ, et al. Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. AIDS 2000; 14:2101-7.
19. Fiscus SA, Cu-Uvin S, Eshete AT, et al. Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy. Clin Infect Dis 2013; 57:290-7.
20. Meditz AL, Moreau KL, MaWhinney S, et al. CCR5 expression is elevated on endocervical CD4+ T cells in healthy postmenopausal women. J Acquir Immune Defic Syndr 2012; 59:221-8.
21. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303: 1526-9.
22. Beignon AS, McKenna K, Skoberne M, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005; 115:3265-75.
23. Berghofer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. J Immunol 2006; 177:2088-96.
24. Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009; 15:955-9.
25. Seillet C, Laffont S, Tremollieres F, et al. The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor alpha signaling. Blood 2012; 119:454-64.
26. Chang JJ, Woods M, Lindsay RJ, et al. Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J Infect Dis 2013; 208:830-8.
27. Guiducci C, Tripodo C, Gong M, et al. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med 2010; 207:2931-42.
28. Odorizzi PM, Wherry EJ. Immunology. An interferon paradox. Science 2013; 340:155-6.
29. Wilson EB, Yamada DH, Elsaesser H, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013; 340:202-7.
30. Teijaro JR, Ng C, Lee AM, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013; 340:207-11.
31. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-12.
32. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24:1228-30.
33. Fitch KV, Srinivasa S, Abbara S, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208:1737-46.
34. Martin GE, Gouillou M, Hearps AC, et al. Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One 2013; 8:e55279.
35. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 2008; 8:737-44.
36. Siddiqui RA, Sauermann U, Altmuller J, et al. X chromosomal variation is associated with slow progression to AIDS in HIV-1-infected women. Am J Hum Genet 2009; 85:228-39.
37. Iwase K, Shimada A, Kawai T, et al. FOXP3/Scurfin gene polymorphism is associated with adult onset type 1 diabetes in Japanese, especially in women and slowly progressive-type patients. Autoimmunity 2009; 42:159-67.
38. Cho J, Kim L, Li Z, Rose NR, Talor MV, Njoku DB. Sex bias in experimental immune-mediated, drug-induced liver injury in BALB/c mice: suggested roles for Tregs, estrogen, and IL-6. PLoS One 2013; 8:e61186.
39. Holmes D, Knudsen G, Mackey-Cushman S, Su L. FoxP3 enhances HIV-1 gene expression by modulating NFkappaB occupancy at the long terminal repeat in human T cells. J Biol Chem 2007; 282:15973-80.
40. Tran TA, de Goer de Herve MG, Hendel-Chavez H, et al. Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy. PLoS One 2008; 3:e3305.
41. Arruvito L, Sanz M, Banham AH, Fainboim L. Expansion of CD4+ CD25+and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. J Immunol 2007; 178:2572-8.
42. Richardson K, Weinberg A. Dynamics of regulatory T-cells during pregnancy: effect of HIV infection and correlations with other immune parameters. PLoS One 2011; 6:e28172.
43. Kolte L. Thymic function in HIV-infection. Dan Med J 2013; 60:B4622.
44. Schulze Zur Wiesch J, Thomssen A, Hartjen P, et al. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol 2010; 85:1287-97.
45. Angin M, Kwon DS, Streeck H, et al. Preserved function of regulatory T cells in chronic HIV-1 infection despite decreased numbers in blood and tissue. J Infect Dis 2012; 205:1495-500.
46. Afshan G, Afzal N, Qureshi S. CD4+CD25(hi) regulatory T cells in healthy males and females mediate gender difference in the prevalence of autoimmune diseases. Clin Lab 2012; 58:567-71.
47. Schiffner T, Sattentau QJ, Dorrell L. Development of prophylactic vaccines against HIV-1. Retrovirology 2013; 10:72.
48. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
49. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-Dadjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347: 1652-61.
50. Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003; 32:452-61.
51. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med 2003; 11:55-9.
52. Currier JS, Spino C, Grimes J, et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000; 24:316-24.
53. Hodder S, Arasteh K, De Wet J, et al. Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med 2012; 13:406-15.
54. Smith KY, Tierney C, Mollan K, et al. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/ lamivudine or tenofovir/emtricitabine. Clin Infect Dis 2014; 58:555-63.